Literature DB >> 21457142

Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy.

Sujoy Khan1, Bodo Grimbacher, Caroline Boecking, Ronnie Chee, Victoria Allgar, Steve Holding, Gabriel Wong, Aarnoud Huissoon, Richard Herriot, Philip Doré, William Sewell.   

Abstract

Therapeutic regimens of intravenous immunoglobulin are currently based on actual body weight. The relationship between immunoglobulin dose and serum IgG level in relation to body size was retrospectively explored in patients on replacement therapy. Data were collected as part of a national audit on immunoglobulin therapy in patients with common variable immunodeficiency. 107 patients received immunoglobulin titrated to optimum effect. Correlations were sought between body mass index, trough IgG levels, infusion frequency and total annual dose. The mean (±SD) trough IgG level was 8.4±1.6 g/L and annual immunoglobulin dose received was 456.8±129.4 g. There was no relationship between annual dose and trough IgG level, regardless of infusion frequency, or adjustment for weight or body mass index. These results support the clinical practice of immunoglobulin prescription by clinical outcome rather than fixed dose by body weight. Future studies exploring immunoglobulin efficacy should include treatment arms with dosages based on both ideal and actual body weight, as ideal body weight-based prescribing would save significant amounts of product. ©2011 Bentham Science Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457142     DOI: 10.2174/187231211795305302

Source DB:  PubMed          Journal:  Drug Metab Lett        ISSN: 1872-3128


  8 in total

Review 1.  Considerations for dosing immunoglobulin in obese patients.

Authors:  J P Hodkinson
Journal:  Clin Exp Immunol       Date:  2017-04-17       Impact factor: 4.330

Review 2.  Bringing immunoglobulin knowledge up to date: how should we treat today?

Authors:  S Misbah; T Kuijpers; J van der Heijden; B Grimbacher; D Guzman; J Orange
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

3.  Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients.

Authors:  J P Hodkinson; M Lucas; M Lee; M Harrison; M P Lunn; H Chapel
Journal:  Clin Exp Immunol       Date:  2015-05-25       Impact factor: 4.330

4.  Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.

Authors:  Philip Wood
Journal:  Ther Clin Risk Manag       Date:  2012-04-02       Impact factor: 2.423

Review 5.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

6.  Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders.

Authors:  Rohan Ameratunga
Journal:  Allergy Asthma Clin Immunol       Date:  2017-12-06       Impact factor: 3.406

Review 7.  A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.

Authors:  Kristin Epland; Daniel Suez; Kenneth Paris
Journal:  Allergy Asthma Clin Immunol       Date:  2022-09-30       Impact factor: 3.373

8.  Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.

Authors:  Lisa Kobrynski
Journal:  Biologics       Date:  2012-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.